Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema~* with macular thickness \> 250 micra using OCT~* visual acuity at least 20/200~* with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease~* patient that can follow study's requirements~* patient who consents to participate~Exclusion Criteria:~* presence of corneal or crystalline opacity preventing observation of fundus of eye~* patients requiring ocular surgery in next 3 months~* one-eyed~* pregnancy and child breastfeeding~* previous history of glaucoma~* on treatment woth an experimental ocular drug~* previous thromboembolism or receiving oral anticoagulant treatment~* vitrectomy~* patients with proved tractional macular pathology associated to macular oedema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab (Type: EXPERIMENTAL): intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
- triamcinolone acetonide (Type: EXPERIMENTAL): intravitreous triamcinolone 2 mg, frequency: 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).